Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “adenosine”

64 pharma patents match "adenosine" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 64
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 64 pharmaceutical patents matching "adenosine" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

64 results for “adenosine” · 30,257 patents in full index Clear search

  1. US 12378248

    A1 adenosine receptor agonists and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12325708

    Adenosine 2 receptor antagonists

    Nektar Therapeutics · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  3. US 12310965

    Treatment of cancer utilizing an identified adenosine fingerprint

    Arcus Biosciences, Inc. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  4. US 12213990

    A3 adenosine receptor ligand for use for achieving a fat loss effect

    CAN-FITE BIOPHARMA LTD. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  5. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  6. US 12168023

    Inhibitors of adenosine 5′-nucleotidase

    Arcus Biosciences, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  7. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  8. US 11795443

    Uses of adenosine base editors

    Beam Therapeutics Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  9. US 11591579

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  10. US 11584923

    Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

    HALOZYME, INC. · Granted Feb 21, 2023 · Expires Feb 16, 2043

    granted
  11. US 11471528

    Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

    The Government of the United States of America as represented by the Secretary of the Department · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  12. US 11396647

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  13. US 11254686

    Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

    Corvus Pharmaceuticals, Inc. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  14. US 11246871

    Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

    Northwestern University · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  15. US 11155803

    Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequence

    Beam Therapeutics Inc. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  16. US 11118167

    Enzyme-mediated depletion of adenosine and/or methylthioadenosine

    The Board of Regents of the University of Texas System · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted
  17. US 11058704

    Inhibitors of adenosine 5′-nucleotidase

    Arcus Biosciences, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  18. US 11040091

    Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

    The Regents of the University of California · Granted Jun 22, 2021 · Expires Jun 17, 2041

    granted
  19. US 10583180

    Method for treating adenosine deaminase severe combined imunodeficiency

    The Regents of the University of California · Granted Mar 10, 2020 · Expires Mar 5, 2040

    granted
  20. US 10577368

    A3 adenosine receptor agonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  21. US 10376515

    Analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activating enzyme ATG7

    Northwestern University · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted
  22. US 10314908

    Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

    The United States of America as represented by the Secretary of the Department of · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted
  23. US 10265337

    Use of A3 adenosine receptor agonist in osteoarthritis treatment

    CAN-FITE BIOPHARMA LTD. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  24. US 10016432

    Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted